Intercure logo

Intercure

INCR
Last price US$0.94
Market cap US$51.4m
12M price change -38.96%
Loading the 12-month Mave Thesis and 1-month news signal

Dashboard Funda..tals Prediction Screener Map

Intercure Overview

Industry: Drug Manufacturers Specialty & Generic

Sector: Healthcare

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel. InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed se Read More

Mavefund brings filings, fundamentals, valuation, price history and news for Intercure into one research view. The sections below show what strengthens or weakens the research case.

Score

Reported Results

What the company reported, with filing details kept small.

Filed Jun 22, 2026

Quarterly result summary

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2026 (Report No. 2) Commission File Number: 001-40...

What changed

  • Review the SEC source filing for the full reported results and management commentary.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

SEC filing Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

Earnings Per Share

Score 2.00/5
Intercure earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Return on Equity

Score 1.96/5
Intercure exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Intercure INCR US$51.4m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Net Margin

Score 2.21/5
Intercure olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Intercure INCR US$51.4m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Share Buyback

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Leverage

Score 2.31/5
Intercure registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
Intercure INCR US$51.4m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

Verified SEC statements load when this section enters view.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Intercure logo

Intercure

US$0.94

US$51.4m

3.29%

-38.96%